Skip to main content

Tables 3 Metabolic status at the baseline and end of trial

From: Clinical and metabolic response to soy administration in older women with metabolic syndrome: a randomized controlled trial

Metabolic indicators Baseline End of trial
Soy-nut TSP Control P value Soy-nut TSP Control P value
TC (mg/dl) 229.9 ± 5.13 229.4 ± 5.84 233.2 ± 5.20 0.87 200.7 ± 4.82a 205.2 ± 5.55a 224.5 ± 5.21 < 0.001
TG (mg/dl) 212.1 ± 8.23 211.9 ± 8.86 212.6 ± 10.65 0.99 199.8 ± 8.65 200.3 ± 9.09 208.5 ± 10.79 0.77
HDL-C (mg/dl) 44.2 ± 1.38 43.0 ± 0.98 44.2 ± 1.58 0.78 46.3 ± 1.17 44.8 ± 0.93 43.7 ± 1.71 0.35
LDL-C (mg/dl) 154.0 ± 3.28 154.7 ± 5.80 152.3 ± 6.01 0.95 131.0 ± 5.42a 134.5 ± 5.65 151.5 ± 6.51 < 0.05
VLDL-C (mg/dl) 41.7 ± 1.56 42.4 ± 1.77 42.4 ± 2.19 0.95 34.5 ± 1.83a 37.4 ± 2.03 42.0 ± 2.28 < 0.05
Apo AI (g/l) 1.8 ± 0.20 1.7 ± 0.22 1.6 ± 0.22 0.77 2.0 ± 0.19 1.9 ± 0.22 1.6 ± 0.21 0.31
Apo B100(g/l) 1.5 ± 0.09 1.5 ± 0.10 1.5 ± 0.17 0.96 1.2 ± 0.07a 1.2 ± 0.09 1.6 ± 0.16 < 0.05
FBG (mg/dl) 104.8 ± 2.01 104.3 ± 2.32 102.5 ± 2.49 0.75 90.4 ± 2.18a 97.8 ± 2.34 99.6 ± 2.83 < 0.05
Insulin (µIU/ml) 12.8 ± 0.79 11.6 ± 0.95 13.4 ± 0.9 0.36 10.8 ± 0.79a 10.8 ± 0.85a 13.8 ± 0.90 < 0.05
HOMA-IR 3.4 ± 0.25 3.0 ± 0.27 3.4 ± 0.25 0.51 2.5 ± 0.21a 2.6 ± 0.23 3.4 ± 0.24 < 0.01
TG/HDL 4.9 ± 0.27 5 ± 0.25 4.9 ± 0.34 0.99 4.41 ± 0.24 4.5 ± 0.24 5 ± 0.39 0.35
CRP (µg/ml) 3.2 ± 0.37 3.1 ± 0.45 3.0 ± 0.49 0.97 2.9 ± 0.38 3.0 ± 0.39 3.0 ± 0.33 0.98
Fibrinogen (mg/dl) 316.7 ± 6.89 316.5 ± 8.88 314.2 ± 9.37 0.97 297.8 ± 6.07 302.0 ± 6.37 306.4 ± 6.59 0.63
MDA (µmol/l) 4.9 ± 0.36 4.9 ± 0.17 5.3 ± 0.28 0.48 4.2 ± 0.35a 4.3 ± 0.19a 5.3 ± 0.25 < 0.001
TAC (µmol/l) 1302.0 ± 45.36 1305.3 ± 45.37 1305.1 ± 40.09 0.99 1516.3 ± 39.70a 1503.4 ± 35.28a 1350.2 ± 47.38 < 0.01
  1. TSP: Textured soy protein; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; TG: triglyceride; HDL-C: high density lipoprotein; LDL-C: low density lipoprotein; VLDL-C: very low density lipoprotein; Apo AI: apolipoprotein AI; Apo B100: apolipoprotein B100; FBG: fasting blood glucose; HOMA-IR: homeostasis model of assessment insulin resistance; TG/HDL-C: triglyceride/high density lipoprotein; MDA: malondialdehyde; TAC: total antioxidant capacity; CRP: C-reactive protein
  2. Values are mean ± standard error
  3. aThere was a significant difference in the treatment groups compared with control group (post hoc ANOVA)